Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Marathon Digital Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Marathon Digital Holdings Inc trades at $9.63 (market cap $3.74B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.9× Marathon Digital Holdings Inc's market cap, and Marathon Digital Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MARA | |
|---|---|---|
Market Cap | $29.60B | $3.74B |
Sector | Health | Technology |
52-Week High | $491.22 | $22.84 |
52-Week Low | $205.48 | $6.73 |
Enterprise Value | $27.56B | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
MARA Holdings trades at $9.64, down 6% post-Q2 2026 results, with a bearish technical signal and negative earnings trends. The company reported a net loss of $1.31 billion in 2025, with revenue declining to $804 million in 2026. Recent news highlights a strategic pivot to AI infrastructure, but investor sentiment remains cautious amid Bitcoin mining sector weakness.
Outlook is mixed: analyst consensus targets $16.08 (67% upside), but high losses and sector volatility pose risks. The AI transition offers growth potential, yet execution challenges and persistent negative margins demand caution. Near-term pressure from missed earnings and competitive threats may limit upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
